2.7800
-0.2300
(-7.64%)
At close: January 10 at 4:00:02 PM EST
2.8300
+0.05
+(1.80%)
After hours: 7:40:42 PM EST
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
2,162.0000
--
--
--
--
Operating Expense
558,816.0000
99,822.0000
119,734.0000
93,318.0000
43,551.0000
Operating Income
-559,516.0000
-99,822.0000
-119,734.0000
-93,318.0000
-43,551.0000
Net Non Operating Interest Income Expense
27,771.0000
24,611.0000
7,448.0000
2,963.0000
1,945.0000
Other Income Expense
-536.0000
-591.0000
8,087.0000
3,507.0000
-53.0000
Pretax Income
-532,281.0000
-75,802.0000
-104,199.0000
-86,848.0000
-41,659.0000
Net Income Common Stockholders
-532,281.0000
-75,802.0000
-104,199.0000
-86,848.0000
-41,659.0000
Diluted NI Available to Com Stockholders
-532,281.0000
-75,802.0000
-104,199.0000
-86,848.0000
-41,659.0000
Basic EPS
-2.18
-0.35
-0.48
-0.44
-0.19
Diluted EPS
-2.18
-0.35
-0.48
-0.44
-0.19
Basic Average Shares
239,162.2500
218,880.0000
216,721.0000
197,887.0000
217,650.0550
Diluted Average Shares
239,162.2500
218,880.0000
216,721.0000
197,887.0000
217,650.0550
Total Operating Income as Reported
-559,516.0000
-99,822.0000
-119,734.0000
-93,318.0000
-43,551.0000
Total Expenses
561,678.0000
99,822.0000
119,734.0000
93,318.0000
43,551.0000
Net Income from Continuing & Discontinued Operation
-532,281.0000
-75,802.0000
-104,199.0000
-86,848.0000
-41,659.0000
Normalized Income
-532,754.0000
-76,160.0000
-113,158.0000
-90,999.0000
-41,877.0000
Interest Income
28,023.0000
24,611.0000
7,448.0000
2,963.0000
1,945.0000
Net Interest Income
27,771.0000
24,611.0000
7,448.0000
2,963.0000
1,945.0000
EBIT
-556,049.0000
-99,822.0000
-119,734.0000
-93,318.0000
-43,551.0000
EBITDA
-555,530.0000
-99,600.0000
-119,535.0000
-93,134.0000
-43,448.0000
Reconciled Depreciation
519.0000
222.0000
199.0000
184.0000
103.0000
Net Income from Continuing Operation Net Minority Interest
-532,281.0000
-75,802.0000
-104,199.0000
-86,848.0000
-41,659.0000
Total Unusual Items Excluding Goodwill
473.0000
358.0000
8,959.0000
4,151.0000
218.0000
Total Unusual Items
473.0000
358.0000
8,959.0000
4,151.0000
218.0000
Normalized EBITDA
-556,003.0000
-99,958.0000
-128,494.0000
-97,285.0000
-43,666.0000
12/31/2020 - 8/26/2020
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
VOR Vor Biopharma Inc.
1.5550
-4.60%
SWTX SpringWorks Therapeutics, Inc.
43.00
+6.20%
VTYX Ventyx Biosciences, Inc.
2.0800
-7.56%
IPSC Century Therapeutics, Inc.
0.9900
-7.48%
LYEL Lyell Immunopharma, Inc.
0.6040
-7.32%
TSHA Taysha Gene Therapies, Inc.
1.7600
-8.81%
RLAY Relay Therapeutics, Inc.
4.4500
-7.87%
CMPX Compass Therapeutics, Inc.
1.7700
-4.84%
IDYA IDEAYA Biosciences, Inc.
24.03
-3.30%
STOK Stoke Therapeutics, Inc.
9.00
+0.45%